NASDAQ:COGT Cogent Biosciences (COGT) Stock Price, News & Analysis $31.21 -0.10 (-0.32%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$31.50 +0.29 (+0.91%) As of 10/23/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cogent Biosciences Stock (NASDAQ:COGT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cogent Biosciences alerts:Sign Up Key Stats Today's Range$30.33▼$31.2750-Day Range$28.09▼$37.8752-Week Range$13.78▼$43.73Volume1.77 million shsAverage Volume2.22 million shsMarket Capitalization$5.42 billionP/E RatioN/ADividend YieldN/APrice Target$51.56Consensus RatingModerate Buy Company Overview Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company uses molecular biology and drug-discovery technologies to design therapies intended to target disease-driving mutations while limiting activity in healthy tissues. Cogent’s lead product candidate is bezuclastinib, also known as CGT9486, an investigational, highly selective inhibitor of the KIT D816V mutation. The company is developing bezuclastinib for systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, including both indolent and advanced forms of the disease. Cogent conducts its research and clinical-development activities primarily in the United States and works with clinical centers and research partners in support of its development programs. The company is headquartered in Boulder, Colorado, and is led by President and Chief Executive Officer Andrew Robbins.AI Generated. May Contain Errors. Read More Cogent Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreCOGT MarketRank™: 2.487292669875 of 5 starsCogent Biosciences scored higher than 50% of companies evaluated by MarketBeat, and ranked 515th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCogent Biosciences has a consensus price target of $51.56, representing about 65.2% upside from its current price of $31.21.Amount of Analyst CoverageCogent Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cogent Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($2.23) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -14.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -14.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 8.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cogent Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.01% of the float of Cogent Biosciences has been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 8.08.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 7.37%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.57 News SentimentCogent Biosciences has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cogent Biosciences this week, compared to 4 articles on an average week.Search Interest3 people have searched for COGT on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders6.59% of the stock of Cogent Biosciences is held by insiders.Percentage Held by InstitutionsCogent Biosciences has minimal institutional ownership at this time.Read more about Cogent Biosciences' insider trading history. Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COGT Stock News HeadlinesCogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?October 20, 2026 | insidermonkey.comCogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDASeptember 25, 2026 | finance.yahoo.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 24 at 1:00 AM | The Oxford Club (Ad)Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?September 24, 2026 | finance.yahoo.comCogent Biosciences (COGT) Looks Fully Valued Following FDA NDA AcceptanceSeptember 24, 2026 | finance.yahoo.comCogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027September 15, 2026 | rttnews.comCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)September 15, 2026 | globenewswire.comCogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCienciaSeptember 2, 2026 | marketscreener.comMSee More Headlines COGT Stock Analysis - Frequently Asked Questions How have COGT shares performed this year? Cogent Biosciences' stock was trading at $35.52 at the beginning of 2026. Since then, COGT shares have decreased by 12.1% and is now trading at $31.21. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) released its quarterly earnings results on Monday, August, 10th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.03. When did Cogent Biosciences IPO? Cogent Biosciences (COGT) raised $75 million in an initial public offering on Thursday, March 29th 2018. The company issued 5,770,000 shares at a price of $12.00-$14.00 per share. Who are Cogent Biosciences' major shareholders? Cogent Biosciences' top institutional shareholders include Assenagon Asset Management S.A. (0.68%) and Sterling Capital Management LLC. Insiders that own company stock include Fairmount Funds Management Llc, John Edward Robinson, Jessica Sachs and Evan Kearns. View institutional ownership trends. How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Micron Technology (MU), NVIDIA (NVDA), Viveve Medical (VIVE), WAVE Life Sciences (WVE), Boeing (BA), Applied Materials (AMAT) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings8/10/2026Today10/24/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 9 days, COGT's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:COGT CIK1622229 Webwww.cogentbio.com Phone(617) 945-5576FaxN/AEmployees258Year Founded2014Price Target and Rating Average Price Target for Cogent Biosciences$51.56 High Price Target$67.00 Low Price Target$35.00 Potential Upside/Downside+65.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$328.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-84.47% Return on Assets-47.72% Debt Debt-to-Equity Ratio0.48 Current Ratio13.57 Quick Ratio13.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.84 per share Price / Book8.13Miscellaneous Outstanding Shares173,525,000Free Float162,090,000Market Cap$5.42 billion OptionableOptionable Beta0.31 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:COGT) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersCrashGPT coming on Dec. 18 …Sam Altman is expected to reveal a confidential OpenAI document around 4 p.m. on Dec. 18, just weeks before a ...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
